Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — ShareCafe Micro/Small Cap "Hidden Gems" Webinar (January 2021)
14 slides from Kazia Therapeutics's conference presentation, Jan 22, 2021
Slide 1: Kazia presents to ShareCafe Hidden Gems webinar (ASX release)
ASX RELEASE 22 January 2021 KAZIA PRESENTS TO SHARECAFE “HIDDEN GEMS” WEBINAR Sydney, 2 January 2021 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to provide a copy of the presentation to be made by our CEO, Dr James Garner to
Slide 2: ASX release continuation
I clinical trial in Australia and the United States. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015. For more information, please visit www.kaziatherapeutics.com. This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Ma
Slide 3: A company developing innovative, high-impact drugs for cancer
A company developing innovative, high-impact drugs for cancer Presentation to ShareCafe ‘Hidden Gems’ Dr James Garner Chief Executive Officer & Managing Director 21 January 2021 ASX: KZA | NASDAQ : KZIA | Twitter: @KaziaTx
Slide 4: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe- harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 5: Corporate Overview
Corporate Overview Oncology-focused, late-clinical-stage, small-molecule Company biotechnology company, headquartered in Sydney, Description Australia Paxalisib – brain-penetrant PI3K / mTOR inhibitor in pivotal study for glioblastoma Pipeline Cantrixil – cancer stem cell-targeting agent in phase I
Slide 6: Investment Rationale
Investment Rationale • Paxalisib developed by Genentech, the world’s most successful cancer drug company • Well-proven mechanism of action, with unique differentiating factor of brain penetration World-Class Asset • Strong scientific rationale for development in brain cancer in Brain Cancer • Encour
Slide 7: Strong progress was made in 4Q CY2020
Strong progress was made in 4Q CY2020 September Agreement with Dana-Farber Cancer Further expansion of clinical program validates 2020 Institute to launch new study in PCNSL paxalisib and potentially expands future use October Oversubscribed funding round Funding allows immediate 2020 raised AU$ 25
Slide 8: Latest phase II data compares well to historical data for temozolomide
Latest phase II data compares well to historical data for temozolomide (existing standard of care) Progression-Free Survival (PFS) Overall Survival (OS) (n=30) (n=30) Paxalisib 8.4 months Paxalisib 17.5 months Median PFS Median OS Existing 5.3 months Existing 12.7 months Therapy Median PFS Therapy M
Slide 9: A broad-based clinical program is underway across multiple forms of brain cancer
A broad-based clinical program is underway across multiple forms of brain cancer Paxalisib (GDC-0084) Primary Brain Cancer Secondary Brain Cancer (brain cancer that begins in the brain) (brain cancer that spreads from elsewhere in the body) Glioblastoma Glioblastoma DIPG Primary CNS Brain Breast Bra
Slide 10: GBM AGILE is currently operational at sites in US and Canada
GBM AGILE is currently operational at 35 sites in US and Canada, and will open EU and China in CY2021 Henry Ford Cancer Institute in Detroit, MI is first site to begin recruiting to paxalisib Source: www.gcaresearch.org 7
Slide 11: Positive newsflow has supported revaluation of Kazia
Positive newsflow has supported revaluation of Kazia as paxalisib moves towards commercialisation Share Price (AU$) KZA 2.00 Market Capitalisation ~AU$ 165 million 1.80 Shares on Issue ~126 million 1.60 ASX: KZA Listing 1.40 NASDAQ: KZIA (1:10 ratio) 1.20 Willoughby Capital 16% Platinum Asset Mgmt.
Slide 12: Key Objectives for CY2021
Key Objectives for CY2021 Execute on GBM AGILE study Drive data from broader paxalisib program Intensify partnering activity Commence ‘rolling NDA’ filing activities 9
Slide 13: Key Milestones and Anticipated Newsflow
Key Milestones and Anticipated Newsflow Execution of definitive agreement with GCAR for GBM AGILE pivotal study October 2020 ✓ Further interim data from Kazia phase II glioblastoma trial November 2020 ✓ Initial interim data from phase I DIPG trial at St Jude November 2020 ✓ Commencement of recruitme
Slide 14: www.kaziatherapeutics.com
www.kaziatherapeutics.com
Kazia Therapeutics — ShareCafe Micro/Small Cap "Hidden Gems" Webinar (January 2021) on 6ix